Corporate | 1 November 2012 08:30
|
MediClin AG / Key word(s): Interim Report
Group sales of the first nine months of FY 2012 increased by 4.4 percent Offenburg, 01 November 2012 – In the first nine months of FY 2012 MEDICLIN Aktiengesellschaft (MediClin) has achieved Group sales of EUR 383.8 mill. (9 M 2011: EUR 367.7 mill.) which were EUR 16.1 mill. or 4.4 % higher than in the same period of last year. EUR 13.6 mill. of the sales increase were attributed to the post-acute segment. Sales of the acute segment were EUR 150.8 mill. (9 M 2011: EUR150.7 mill.) thus on previous year's level, sales of the business field nursing care increased by EUR 1.0 mill. up to EUR 9.8 mill. (9 M 2011: EUR 8.8 mill.). The Group operating result of EUR 6.2 mill. (9 M 2011: EUR 7.0 mill.) was EUR 0.8 mill. lower than in the same period of last year. The previous year's value contained aperiodic releases of provisions in the amount of EUR 2.9 mill. Adjusted by these special effects the Group operating result for the first nine months of FY 2012 would be EUR 2.0 mill. higher than the previous year's value. Less other operating income in the amount of EUR 3.1 mill. as well as additional expenses in the amount of in total EUR 13.8 mill. stood against the increase in sales of EUR 16.1. mill. Of the additional expenses EUR 9.0 mill. applied to staff costs, EUR 3.4 mill to other operating expenses, EUR 0,8 mill. to raw materials and consumables used and EUR 0.7 mill. to depreciation and amortisation. The Group result attributable to shareholders of MediClin amounted to EUR 2.4 mill. (9 M 2011: EUR 0.6 mill.). The un-/diluted earnings per share for the first nine months of FY 2012 amounted to EUR 0.05 (9 M 2011: EUR 0.01). Post-acute segment clearly above previous year's figures The post-acute segment result of EUR 4.6 mill. has improved significantly in the nine-month comparison. The determining factors were the noticeable sales increase of EUR 13.6 mill. and an only under-proportional increase in expenses. For the same period with sales nearly unchanged and despite increased numbers of nursing days and cases the acute segment result shows a decrease of EUR 5.9 mill. Especially the 4.8 % higher staff costs as well as the 8.5 % higher other operating expenses – here in particular maintenance costs – did burden the result.
Investments are still on a high level
Outlook
The interim report as of 30 September 2012 will be available as of 14 November 2012 under www.mediclin.de in German and English. /
About MediClin AG (Ticker: MED; WKN: 659 510)
End of Corporate News 01.11.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | MediClin AG | |
| Okenstraße 27 | ||
| 77652 Offenburg | ||
| Germany | ||
| Phone: | +49 (0)781 488-189 | |
| Fax: | +49 (0)781 488-184 | |
| E-mail: | alexandra.muehr@mediclin.de | |
| Internet: | www.mediclin.de | |
| ISIN: | DE0006595101 | |
| WKN: | 659510 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 191120 01.11.2012 |